Relapsed Ovarian Cancer
Conditions
Brief summary
This study aims to carry out a multi-center, randomized controlled study on patients with recurrent ovarian cancer after PARPi maintenance, to explore the clinicopathological and molecular characteristics of patients with recurrent ovarian cancer after PARPi maintenance, and to clarify whether patients with recurrent ovarian cancer after PARPi maintenance for more than 6 months are sensitive to platinum drugs, and the value of secondary tumor cell reduction in such treatment, In order to provide evidence-based medicine basis for the standardized treatment mode of recurrent ovarian cancer after PARPi maintenance treatment.
Interventions
PROCEDURESecondary cytoreduction
Open surgery is conducted by senior clinicians in gynecological oncology. Operation time，location and number of relapsed lesions, location and number of excised lesions, Whether achieved R0 or not, and other information are recorded.
DRUGChemotherapy
chemotherapy
Sponsors
Women's Hospital School Of Medicine Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with diagnosis of first-line or second-line recurrent epithelial ovarian carcinoma, peritoneal carcinoma, or fallopian tube carcinoma, who has previously received at least 4 cycles of platinum-based chemotherapy in initial treatment; 2. Relapse occurred after 6 month since platinum-based chemotherapy; 3. PARPi maintenance therapy for more than 6 months before relapse; 4. R0 ideal debulking in initial surgery; 5. PET-CT indicate the recurrence lesion is isolated and not exceed 5 sites, and the ascites is less than 500ml; 6. ECOG/WHO Performance score of 0 to 1; 7. No hepatic failure, bilirubin ≤ 1,5 time the Normal limit, ASAT and ALAT ≤ 3 time the Upper Normal Limit 8. No Renal insufficiency (serum creatinine \< 1,5 time the normal limit, creatinine clearance \> 80 mL/min). calculated with MDRD method 9. Hematology function: PNN ≥ 1,5x10⁹/L, platelets ≥ 100x10⁹/L 10. No contraindication to general anaesthesia for heavy surgery 11. Patients having read, signed and dated Informed consent before any study procedure
Exclusion criteria
1. Platinum-refractory/uncontrolled epithelial ovarian cancer; 2. Non-epithelial ovarian tumor, mucinous, serous-mucinous (mainly mucinous), malignant Brenner tumor, low-grade serous carcinoma, borderline tumor; 3. Suffering from other malignant tumors that have not achieved complete remission in the past 2 years; 4. Received radiotherapy within 2 weeks before the start of the study intervention; 5. General conditions cannot tolerate secondary cytoreduction; 6. Severe hypersensitivity reactions (≥ grade 3) to paclitaxel or platinum and/or any of its excipients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival (PFS) | 18-24 months | progression free survival |
Countries
China
Outcome results
None listed